|Bid||4.76 x 100|
|Ask||5.25 x 1000|
|Day's Range||4.76 - 4.90|
|52 Week Range||3.92 - 8.38|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Dow and S&P 500 are up 8 weeks in a row. Yahoo Finance's Jared Blikre explains what's fueling the record rally in stocks and what investors will be watching this week.
Keryx Biopharmaceuticals Inc (NASDAQ:KERX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
On a per-share basis, the Boston-based company said it had a loss of 26 cents. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Investors in Keryx Biopharmaceuticals (KERX) need to pay close attention to the stock based on moves in the options market lately.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Keryx Biopharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to KERX-US. Comparing the performance and risk of Keryx Biopharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Keryx Biopharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Keryx Biopharmaceuticals, Inc. – Ardelyx, Inc., AMAG Pharmaceuticals, Inc., Impax Laboratories, Inc., Apricus Biosciences, Inc., Sophiris Bio Inc., Momenta Pharmaceuticals, Inc., VIVUS, Inc. and Aeterna Zentaris Inc. (ARDX-US, ... Read more (Read more...)
Shares took a nosedive after the company's earnings report, but with a new FDA approval under its belt, this could be a buying opportunity for investors.
The much-maligned drugmaker is making progress, but it's not out of the woods yet. Plus, why Keryx Pharmaceuticals shares tumbled despite winning a key FDA approval.
Keryx Biopharmaceuticals (NASDAQ:KERX) has commercial adoption challenges ahead for its iron deficiency anemia asset Auryxia, says Cowen analyst Boris Peaker. After the company's drug came up short of the Street to the tune of a $3.6 million miss, slowing prescription growth does not fire up confidence for shareholders.
While focus remained on Regeneron's (REGN) Q3 earnings, Dicerna was also in the news related to its collaboration agreement with Boehringer Ingelheim.
Keryx (KERX) posted wider-than-expected loss in the third quarter of 2017. The company also received approval for label expansion of its lead drug Auryxia.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Keryx Biopharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
If you are looking to invest in Keryx Biopharmaceuticals Inc’s (NASDAQ:KERX), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...
One in four of the company's shares is currently being shorted, but bears appear to be wrong about this pharma stock.